<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34981555</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1531-8249</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>91</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Annals of neurology</Title>
          <ISOAbbreviation>Ann Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Reduced Numbers of Corticotropin-Releasing Hormone Neurons in Narcolepsy Type 1.</ArticleTitle>
        <Pagination>
          <StartPage>282</StartPage>
          <EndPage>288</EndPage>
          <MedlinePgn>282-288</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.26300</ELocationID>
        <Abstract>
          <AbstractText>Narcolepsy type 1 (NT1) is a chronic sleep disorder correlated with loss of hypocretin(orexin). In NT1 post-mortem brains, we observed 88% reduction in corticotropin-releasing hormone (CRH)-positive neurons in the paraventricular nucleus (PVN) and significantly less CRH-positive fibers in the median eminence, whereas CRH-neurons in the locus coeruleus and thalamus, and other PVN neuronal populations were spared: that is, vasopressin, oxytocin, tyrosine hydroxylase, and thyrotropin releasing hormone-expressing neurons. Other hypothalamic cell groups, that is, the suprachiasmatic, ventrolateral preoptic, infundibular, and supraoptic nuclei and nucleus basalis of Meynert, were unaffected. The surprising selective decrease in CRH-neurons provide novel targets for diagnostics and therapeutic interventions. ANN NEUROL 2022;91:282-288.</AbstractText>
          <CopyrightInformation>© 2022 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shan</LastName>
            <ForeName>Ling</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0002-4765-2474</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Sleep Wake Centre SEIN, Heemstede, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Balesar</LastName>
            <ForeName>Rawien</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuropsychiatric Disorders, Netherlands Institute for Neuroscience, An Institute of the Royal Netherlands Academy of Arts and Sciences, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Swaab</LastName>
            <ForeName>Dick F</ForeName>
            <Initials>DF</Initials>
            <Identifier Source="ORCID">0000-0002-9665-7845</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neuropsychiatric Disorders, Netherlands Institute for Neuroscience, An Institute of the Royal Netherlands Academy of Arts and Sciences, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lammers</LastName>
            <ForeName>Gert Jan</ForeName>
            <Initials>GJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Sleep Wake Centre SEIN, Heemstede, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fronczek</LastName>
            <ForeName>Rolf</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Sleep Wake Centre SEIN, Heemstede, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Ann Neurol</MedlineTA>
        <NlmUniqueID>7707449</NlmUniqueID>
        <ISSNLinking>0364-5134</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>9015-71-8</RegistryNumber>
          <NameOfSubstance UI="D003346">Corticotropin-Releasing Hormone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C563534">Narcolepsy 1</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003346" MajorTopicYN="N">Corticotropin-Releasing Hormone</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007031" MajorTopicYN="N">Hypothalamus</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008125" MajorTopicYN="N">Locus Coeruleus</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008473" MajorTopicYN="N">Median Eminence</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009290" MajorTopicYN="N">Narcolepsy</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010286" MajorTopicYN="N">Paraventricular Hypothalamic Nucleus</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>23</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34981555</ArticleId>
        <ArticleId IdType="doi">10.1002/ana.26300</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Bassetti CLA, Adamantidis A, Burdakov D, et al. Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol 2019;15:519-539.</Citation>
        </Reference>
        <Reference>
          <Citation>Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-997.</Citation>
        </Reference>
        <Reference>
          <Citation>Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-474.</Citation>
        </Reference>
        <Reference>
          <Citation>Blouin AM, Thannickal TC, Worley PF, et al. Narp immunostaining of human hypocretin (orexin) neurons: loss in narcolepsy. Neurology 2005;65:1189-1192.</Citation>
        </Reference>
        <Reference>
          <Citation>Crocker A, Espana RA, Papadopoulou M, et al. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 2005;65:1184-1188.</Citation>
        </Reference>
        <Reference>
          <Citation>van de Nes JA, Kamphorst W, Ravid R, Swaab DF. Comparison of beta-protein/A4 deposits and Alz-50-stained cytoskeletal changes in the hypothalamus and adjoining areas of Alzheimer's disease patients: amorphic plaques and cytoskeletal changes occur independently. Acta Neuropathol 1998;96:129-138.</Citation>
        </Reference>
        <Reference>
          <Citation>Thannickal TC, John J, Shan L, et al. Opiates increase the number of hypocretin-producing cells in human and mouse brain and reverse cataplexy in a mouse model of narcolepsy. Sci Transl Med 2018;10:447.</Citation>
        </Reference>
        <Reference>
          <Citation>Swaab DF. The human hypothalamus: basic and clinical aspects. Part 1: nuclei of the human hypothalamus. Amsterdam: Elsevier, 2003.</Citation>
        </Reference>
        <Reference>
          <Citation>Fronczek R, Overeem S, Lee SY, et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 2007;130:1577-1585.</Citation>
        </Reference>
        <Reference>
          <Citation>Vujovic N, Gooley JJ, Jhou TC, Saper CB. Projections from the subparaventricular zone define four channels of output from the circadian timing system. J Comp Neurol 2015;523:2714-2737.</Citation>
        </Reference>
        <Reference>
          <Citation>Shan L, Bossers K, Unmehopa U, et al. Alterations in the histaminergic system in Alzheimer's disease: a postmortem study. Neurobiol Aging 2012;33:2585-2598.</Citation>
        </Reference>
        <Reference>
          <Citation>Dong W, Seidel B, Marcinkiewicz M, et al. Cellular localization of the prohormone convertases in the hypothalamic paraventricular and supraoptic nuclei: selective regulation of PC1 in corticotrophin-releasing hormone parvocellular neurons mediated by glucocorticoids. J Neurosci 1997;17:563-575.</Citation>
        </Reference>
        <Reference>
          <Citation>Romanov RA, Alpár A, Zhang M, et al. A secretagogin locus of the mammalian hypothalamus controls stress hormone release. EMBO J 2015;34:36-54.</Citation>
        </Reference>
        <Reference>
          <Citation>Honda M, Arai T, Fukazawa M, et al. Absence of ubiquitinated inclusions in hypocretin neurons of patients with narcolepsy. Neurology 2009;73:511-517.</Citation>
        </Reference>
        <Reference>
          <Citation>Gao S-F, Qi X-R, Zhao J, et al. Decreased NOS1 expression in the anterior cingulate cortex in depression. Cereb Cortex 2013;23:2956-2964.</Citation>
        </Reference>
        <Reference>
          <Citation>Thannickal TC, Siegel JM, Nienhuis R, Moore RY. Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy. Brain Pathol 2003;13:340-351.</Citation>
        </Reference>
        <Reference>
          <Citation>Gavrilov YV, Ellison BA, Yamamoto M, et al. Disrupted sleep in narcolepsy: exploring the integrity of galanin neurons in the ventrolateral preoptic area. Sleep 2016;39:1059-1062.</Citation>
        </Reference>
        <Reference>
          <Citation>Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000;355:39-40.</Citation>
        </Reference>
        <Reference>
          <Citation>Kok SW, Roelfsema F, Overeem S, et al. Dynamics of the pituitary-adrenal ensemble in hypocretin-deficient narcoleptic humans: blunted basal adrenocorticotropin release and evidence for normal time-keeping by the master pacemaker. J Clin Endocrinol Metab 2002;87:5085-5091.</Citation>
        </Reference>
        <Reference>
          <Citation>Maurovich-Horvat E, Keckeis M, Lattová Z, et al. Hypothalamo-pituitary-adrenal axis, glucose metabolism and TNF-α in narcolepsy. J Sleep Res 2014;23:425-431.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
